Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging

/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA)...

Related Keywords

Australia ,Japan ,United States ,United Kingdom ,Belgium ,China ,Melbourne ,Victoria ,Canada ,Dingwei ,Fujian ,Switzerland ,Australian ,Chinese ,Cdx Illuccix ,Kyahn Williamson ,Davidn Cade ,Telix Asia Pacific ,Telix Pharmaceuticals ,Linkedin ,Drug Administration ,Australian Securities Exchange ,Prnewswire Telix Pharmaceuticals Limited ,Australian Therapeutic Goods Administration ,Group Limited Grand Pharma ,Chinese National Medical Products Administration ,Corporate Communications ,Health Canada ,Pharmaceuticals Limited ,Drug Evaluation ,Positron Emission Tomography ,United States Food ,Grand Pharmaceutical Group Limited ,Grand Pharma ,Greater China ,Asia Pacific ,Prostate Cancer ,Telix Pharmaceuticals Limited ,